[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100654152":3},{"organization":4,"outcomesModule":7,"designInfo":24,"detailedDescription":23,"studyPopulation":27,"armGroups":23,"interventions":23,"overallOfficials":23,"centralContacts":28,"locations":34,"responsibleParty":51,"collaborators":23,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":23,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":23,"enrollmentInfo":62,"targetDuration":65,"studyType":66,"phases":23,"briefSummary":67,"conditions":68,"keywords":23,"overallStatus":37,"whyStopped":23,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":23},[9],{"measure":10,"description":11,"timeFrame":12},"NEI-VFQ-25 scale","The NEI-VFQ-25 (National Eye Institute Visual Function Questionnaire-25) is a 25-item, vision-specific patient-reported outcome measure. It assesses the impact of visual impairment on health-related quality of life","Two years after HSCT",[14,17,20],{"measure":15,"description":16,"timeFrame":12},"EQ-5D-5L","The EQ-5D-5L is a standardized, generic health status measure developed by the EuroQol Group. It is designed for self-completion and is widely used in clinical and economic evaluations.",{"measure":18,"description":19,"timeFrame":12},"Lee GVHD scale","The Lee Chronic GVHD Symptom Scale is a patient-reported outcome (PRO) measure developed to assess the symptom burden of chronic graft-versus-host disease (cGVHD)",{"measure":21,"description":22,"timeFrame":12},"FACT-BMT","The FACT-BMT (Functional Assessment of Cancer Therapy - Bone Marrow Transplantation) is a patient-reported outcome (PRO) measure designed to assess health-related quality of life (HRQoL) in patients undergoing bone marrow or hematopoietic stem cell transplantation",null,{"allocation":23,"interventionModel":23,"interventionModelDescription":23,"primaryPurpose":23,"observationalModel":25,"timePerspective":26,"maskingInfo":23},"COHORT","PROSPECTIVE","Patients after all-HSCT",[29],{"name":30,"role":31,"phone":32,"phoneExt":23,"email":33},"Chuanhe Jiang","CONTACT","0086-021-64370045","jch12191@rjh.com.cn",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Ruijin Hospital, Shanghai Jiaotong University School of Medicine","RECRUITING","Shanghai","Shanghai Municipality","200025","China","CN",{"type":44,"coordinates":45},"Point",[46,47],121.45806,31.22222,{"lat":47,"lon":46},[50],{"name":30,"role":31,"phone":32,"phoneExt":23,"email":33},{"type":52,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100654152","observational-cohort-study-on-ocular-chronic-graft-versus-host-disease-100654152",false,"NCT07794800","Observational Cohort Study on Ocular Chronic Graft-Versus-Host Disease","A Multicenter, Prospective, Non-Interventional Observational Cohort Study on Ocular Chronic Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation - The Bright Study","Inclusion Criteria:\n\n* Age ≥14 years, both genders eligible;\n* First allogeneic hematopoietic stem cell transplantation;\n\n  * 100 days post-transplantation, with donor hematopoietic stem cell engraftment confirmed;\n* The subject or their legally authorized representative has provided full informed consent, signed the informed consent form, and is willing to complete subsequent follow-up visits\n\nExclusion Criteria:\n\n* Preexisting moderate-to-severe ocular surface disease prior to transplantation;\n* Active ocular infection;\n* Presence of other ocular conditions that, in the opinion of the ophthalmologist, may significantly affect the diagnosis of chronic ocular graft-versus-host disease, the evaluation of ocular surface parameters, or the completion of long-term follow-up;\n* Patients with active hematologic malignancies.","ALL","14 Years",{"count":63,"type":64},340,"ESTIMATED","2 Years","OBSERVATIONAL","This study is a multicenter, prospective, observational cohort study designed to enroll a total of 340 patients undergoing allogeneic hematopoietic stem cell transplantation. Through comprehensive evaluations by hematology departments, ophthalmology departments, and patient-reported outcomes, the study aims to assess patient-reported outcomes, overall incidence, risk factors, and other clinical outcomes in patients with chronic ocular graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.",[69],"Chronic Graft Versus Host Disease in Eye","2026-08-27",{"date":72,"type":73},"2026-08-31","ACTUAL",{"date":75,"type":73},"2026-06-01",{"date":77,"type":64},"2030-06-01",{"name":5,"class":6},1]